US Capitol Capsule: Biosimilars Uptake Will Fail Without Trust, Accountability

While achieving a robust US biosimilars market is going to be an "incremental" process influenced by a variety of factors, the most critical element in getting to success is gaining the trust of the prescribing community, said Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research.